Page 17 - Human Use News Today

Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. ...

The New York Stock Exchange continues its upward trend, with the S&P500 up 0.3% and the Dow Jones up 0.4%, following a session euphorically driven by Nvidia, a veritable locomotive for the US markets...

23.02.2024 - SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to ... Seite 1

Luspatercept has been recommended for approval by the EMA for patients with transfusion-dependent anemia and lower-risk myelodysplastic syndromes.

Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.

By Colin Kellaher Merck & Co. on Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug...

The European Medicines Agency granted marketing authorization for tislelizumab and retifanlimab for the treatment of non–small cell lung cancer and Merkel cell carcinoma, respectively.

The vaccines, Celldemic and Incellipan, protect against the H5N1 subtype of the influenza A virus.

Treatments for amyotrophic lateral sclerosis and paroxysmal nocturnal hemoglobinuria have been given marketing authorization by the European Medicines Agency.

BioPharma